posted on 2023-04-03, 21:41authored byBrett L. Ecker, Amanpreet Kaur, Stephen M. Douglass, Marie R. Webster, Filipe V. Almeida, Gloria E. Marino, Andrew J. Sinnamon, Madalyn G. Neuwirth, Gretchen M. Alicea, Abibatou Ndoye, Mitchell Fane, Xiaowei Xu, Myung Shin Sim, Gary B. Deutsch, Mark B. Faries, Giorgos C. Karakousis, Ashani T. Weeraratna
Figure S1
Funding
NIH
Melanoma Research Alliance
History
ARTICLE ABSTRACT
Older patients with melanoma have lower rates of sentinel lymph node (LN) metastases yet paradoxically have inferior survival. Patient age correlated with an inability to retain Technetium radiotracer during sentinel LN biopsy in more than 1,000 patients, and high Technetium counts correlated to better survival. We hypothesized that loss of integrity in the lymphatic vasculature due to extracellular matrix (ECM) degradation might play a role. We have implicated HAPLN1 in age-dependent ECM degradation in the dermis. Here, we queried whether HAPLN1 could be altered in the lymphatic ECM. Lymphatic HAPLN1 expression was prognostic of long-term patient survival. Adding recombinant HAPLN1 to aged fibroblast ECMs in vitro reduced endothelial permeability via modulation of VE-cadherin junctions, whereas endothelial permeability was increased following HAPLN1 knockdown in young fibroblasts. In vivo, reconstitution of HAPLN1 in aged mice increased the number of LN metastases, but reduced visceral metastases. These data suggest that age-related changes in ECM can contribute to impaired lymphatics.
Our studies reveal that changes in the stroma during aging may influence the way tumor cells traffic through the lymphatic vasculature. Aging may dictate the route of metastatic dissemination of tumor cells, and understanding these changes may help to reveal targetable moieties in the aging tumor microenvironment.See related commentary by Marie and Merlino, p. 19.This article is highlighted in the In This Issue feature, p. 1